[Ip-health] Merck, BMS and Gilead Lose Atripla U.K. Patent Extension

Sean Flynn sflynn at wcl.american.edu
Fri Mar 24 05:02:35 PDT 2017

BNA World IP reports that Merck Sharp & Dohme Corp. lost its U.K. patent protection extension on its Atripla HIV-treatment cocktail March 22.

Sean Flynn
Director, LLM in Intellectual Property
Acting Director, Program on International Organizations, Law and Diplomacy
Associate Director, Professorial Lecturer in Residence, Program on Information Justice and Intellectual Property
American University Washington College of Law

More information about the Ip-health mailing list